tirzepatide nash for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial Tirzepatide for the treatment of

Increase visibility and revenue

New peer-reviewed research shows that comprehensive clinical support is a decisive factor in...

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

She noticed a 15-pound weight loss and debilitating fatigue within that timeframe

Compared to controls, bilirubin-treated mice exhibited reductions in body weight, blood glucose levels, total cholesterol (TC), leptin, total and direct bilirubin and increases in adiponectin and expression of SREBP-1, IR and PPAR mRNA

* (Lys26)